Di Minno et al. not only showed that patients with psoriatic arthritis demonstrate higher MPA and HPR rates than healthy controls, but also that patients with minimal disease activity during TNF-α inhibitor treatment exhibit comparable platelet aggregation to that seen in controls. This evidence concerns the gene TNF and psoriatic arthritis.